1. Introduction {#sec1}
===============

Diabetes mellitus is a serious metabolic disorder characterized by hyperglycemia and various life-threatening complications. Despite enormous preventive efforts, diabetes mellitus is one of the fastest growing chronic disorders across the world. In 2010, an estimated 285 million people worldwide suffered from diabetes mellitus, and the number of people with diabetes mellitus is expected to rise to 439 million or 7.7% of the global adult population aged 20--79 yr by 2030 [@bib1]. According to the Korean National Health and Nutrition Examination Survey conducted in 2013, the prevalence of diabetes mellitus in Korea for adults over age 30 yr was estimated to be 11.0% [@bib2].

Although no cure is yet available for diabetes mellitus, various pharmacologic agents have been developed and are being used to enable blood glucose control. However, the current pharmaceuticals for diabetes mellitus have a number of limitations, such as having adverse effects and high rates of failure in long-term glycemic control. This has led to research for alternative or complementary approaches, such as natural products or botanicals, which have some degree of efficacy and mostly are without the troublesome side effects associated with the conventional pharmacologic treatments. Furthermore, earlier intervention for glycemic control is being emphasized for prevention or delay of diabetes mellitus in the management of patients with prediabetes [@bib3]. In this context, alternative approaches using natural products may provide additional strategies for the early management of diabetes mellitus or prediabetes.

Ginseng is a slow-growing perennial herb that has been used as a traditional medicine for thousands of years in Asia. Ginseng has been reported to have various pharmacological properties, including anticancer, antiaging, anti-inflammatory, and antiallergy effects [@bib4], [@bib5], [@bib6], [@bib7]. Ginseng has also received attention from medical researchers for its antihyperglycemic effects, which have been demonstrated by *in vitro* [@bib8], [@bib9] and *in vivo* animal studies [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19] and clinical trials [@bib20], [@bib21], [@bib22]. Although both root and berry of ginseng were reported to possess antihyperglycemic effects, a recent *in vivo* study demonstrated that ginseng berry had more potent antihyperglycemic effects than its root when used at the same dosages [@bib23]. Indeed, the ginseng berry has a distinct ginsenoside profile and contains significantly more ginsenosides than its root [@bib23], [@bib24]. For this reason, the ginseng berry may exert more potent antihyperglycemic effects than its root. However, the antihyperglycemic effects of *Panax ginseng* berry have never been explored in humans. Therefore, the objective of the present study was to test the efficacy and safety of a 12-wk treatment with ginseng berry in participants with fasting glucose level between 100 mg/dL and 140 mg/dL, using a randomized, double-blind, placebo-controlled study design.

2. Materials and methods {#sec2}
========================

2.1. Preparation of ginseng berry extract and HPLC analysis {#sec2.1}
-----------------------------------------------------------

Ginseng berry and placebo capsules were provided by Amorepacific Corporation (Gyeonggi, Korea). Freshly harvested 4-yr-old Korean ginseng berries (*P. ginseng* Meyer) cultivated in Chungbuk province of South Korea were used. The seeds were separated, and the pulp and juice dried in hot air. The dried ginseng berries were refluxed with 70% ethanol for 10 h. The extract was filtered and evaporated under vacuum at 45°C to obtain standardized Korean ginseng berry extract. The concentration of seven major ginsenosides in ginseng berry extract was analyzed by HPLC ([Fig. 1](#fig1){ref-type="fig"}) [@bib25]. Total ginsenoside concentrations (% w/w) were 19.99%. Individual ginsenoside concentrations were 0.77%, 1.90%, 2.11%, 1.65%, 11.06%, 1.66%, and 0.84% for the ginsenosides Rb1, Rb2, Rc, Rd, Re, Rg1, and Rg2, respectively. The content of ginsenoside Re in standardized ginseng berry extract was maintained at 10%. Each 500-mg ginseng berry capsule contained 250 mg of standardized ginseng berry extract. The total treatment dose of ginseng berry extract was 1 g/d. Placebo capsules were identical in appearance and flavor to the ginseng berry capsules. During the trials, four capsules (2 capsules at a single time before breakfast and dinner) of ginseng berry extract or placebo were given daily for 12 wk.Fig. 1HPLC of ginseng berry extract. AU, absorbance units.

2.2. Participants {#sec2.2}
-----------------

The study participants were recruited from January 2014 to December 2014 in Dongguk University Ilsan Hospital (Koyang, Gyeonggi, Korea) via hospital and subway advertisement. After the screening test, participants with fasting blood glucose within a range of 100--140 mg/dL, whose age was between 20 yr and 75 yr, were enrolled in this study. Exclusion criteria included: lipid metabolism disorders; acute or chronic inflammatory disease; corticosteroid use within 4 wk of the study; acute cardiovascular disease such as heart failure, myocardial infarction, or stroke; an allergy or hypersensitivity to any of the ingredients in the test products; a history of disease that could interfere with the test products or impede their absorption, such as gastrointestinal diseases or gastrointestinal surgery; participation in other clinical trials within the previous 2 mo; renal disease such as acute/chronic renal failure or nephrotic syndrome; abnormal hepatic liver function; use of antipsychosis drug therapy within 2 mo of the study; a history of alcohol or substance abuse; pregnancy or breast feeding; and laboratory test results, medical, or psychological conditions that the researchers considered unsuitable for this study. In addition, participants taking glucose-lowering medications or insulin injections were excluded from this study. This study was carried out in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board of Dongguk University Ilsan Hospital (IRB No. 2013-81). A total of 72 participants were enrolled in this study and provided their written informed consent for the study after they were provided with a detailed description of the experimental procedures and informed that they could withdraw from the study at any time.

2.3. Study design {#sec2.3}
-----------------

This study was designed as a single-center, randomized, double-blind, placebo-controlled clinical trial that lasted for 12 wk. Following the screening visit, at which inclusion and exclusion criteria were assessed, participants were randomly assigned to receive ginseng berry extract or placebo using a computerized method of random list generation. All participants, investigators, pharmacists and study personnel were blinded to treatment allocation. The enrolled participants were scheduled to visit three times (at 0 wk, 6 wk, and 12 wk) during the trial and their clinical information and trial data were collected during individual interviews conducted by a well-trained interviewer. All participants underwent a thorough medical history review and a physical examination. Height and weight were obtained using standardized techniques and equipment. Height was measured to the nearest 0.1 cm and weight was measured to the nearest 0.1 kg. The body mass index (BMI) was calculated as body weight in kg divided by the square of height in m (kg/m^2^). Participants were questioned about their daily food intake by the 24-h recall method and physical activity during the past 7 d. Compliance with study restriction and capsule consumption was monitored by means of daily documentation by participants on individualized study calendars and count of returned capsules on the second and third visit. During the intervention period, participants were prohibited from glucocorticoid treatments, glucose-lowering medications or insulin injections, thyroid medications, and any medication or functional food that the researchers considered unsuitable.

2.4. Measurements of efficacy {#sec2.4}
-----------------------------

The primary efficacy measure was changes of fasting and postprandial glucose concentration during the 75 g oral glucose tolerance test (OGTT) before and after intervention. The secondary efficacy measures were changes of fasting and postprandial insulin, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and total cholesterol levels. At 0 wk and 12 wk, a 75 g OGTT was performed after an overnight fast (fasting for at least 8 h). Venous blood samples were then collected at 0 min, 60 min, and 120 min for measurements of serum glucose and insulin levels. Also, fasting blood samples were collected at each visit to measure the lipid profile. Tubes were centrifuged at 2000× *g* to isolate plasma or serum, and stored at --70°C until analysis. Blood samples were analyzed on a Cobas c702 analyzer (Roche Diagnostics, Basel, Switzerland). Serum glucose concentrations were measured using the hexokinase method with a Cobas c702 analyzer (Roche Diagnostics). Serum insulin concentrations were measured by the electrochemiluminescence immunoassay using a Cobas c602 analyzer (Roche Diagnostics). The homeostasis model assessment of insulin resistance (HOMA-IR) and β cell function (HOMA-β cell) were calculated using the following equations:

Hemoglobin A1c (HbA1c) was measured by an G8 glycohemoglobin analyzer (Tosoh Corporation, Tokyo, Japan) using the HPLC method. Fasting serum concentrations of triglyceride and total cholesterol were measured using the enzymatic colorimetric method with a Cobas c702 analyzer (Roche Diagnostics). High-density lipoprotein and low-density lipoprotein cholesterol were measured by the homogeneous enzymatic colorimetric method with a Cobas c702 analyzer (Roche Diagnostics).

2.5. Assessment of safety {#sec2.5}
-------------------------

Safety was assessed by adverse events reported by participants, physical examination, and laboratory parameters. During the trial, all participants were asked to report potential adverse events. Vital sign of each participant including systolic and diastolic blood pressure and pulse rate was measured at every visit. Systolic and diastolic blood pressure was measured using the left arm of the seated patient with an automatic blood pressure monitor after resting for \> 5 min. Pulse rate per min was determined by counting the number of beats on the participant\'s wrist for 15 s and multiplying this number by 4 to yield beats/min. Laboratory parameters including complete blood count, alkaline phosphatase, aspartate transaminase, alanine aminotransferase, total protein, albumin, blood urea nitrogen, and creatinine were measured at 0 wk and 12 wk as part of a safety assessment.

2.6. Statistical analyses {#sec2.6}
-------------------------

Differences in mean change from baseline between the treatment groups were examined using the linear mixed model for repeated measures data unless otherwise specified. A paired *t* test was used to determine significance of change from baseline within each treatment group. The demographic and baseline characteristics of each treatment group were compared by the independent *t* test for the continuous variables or χ^2^-test for the categorical data. All *p* values shown are two-tailed. A *p* value \< 0.05 was considered significant. Calculations and statistical analyses were performed using SPSS (version 18.0.0; SPSS Inc., Chicago, IL, USA). All the data were represented as mean ± standard deviation.

2.7. Analyzing metabolomics profiling from serum and data processing {#sec2.7}
--------------------------------------------------------------------

The metabolomics profiling from serum of study participants were analyzed. UPLC coupled to quadrupole time-of-flight (Q-TOF)--MS analysis was performed using an Acquity UPLC system (Waters, Miliford, MA, USA). The column was an ACQUITY UPLC BEH C18 column (2.1 mm × 100 mm, 1.7μm, Waters) at a flow rate of 0.35 mL/min. The mobile Phase A was water with 0.1% formic acid, and mobile phase B was acetonitrile with 0.1% formic acid. The gradient conditions were 0.5% B rising to 70% in 8 min to a maximum 90% after 8 min and then the equilibrated at 0.5% B for 2 min. The Q-TOF-MS was operated in positive and negative electrospray ionization mode within a mass range of 50--1,000 m/z. The operating parameters were as follows: cone voltage, 30 V; a capillary voltage, 3.0 kV; source temperature, 150°C; desolvation gas temperature, 300°C. The raw data were processed using Progenesis QI data analysis software (Nonlinear Dynamic, Newcastle, UK) for chromatographic alignment, normalization, peak picking, and compound identification. The resulting data sets were imported into SIMCA-P version 12.0.1 (Umetrics, Umeå, Sweden) for multivariate analysis and were mean-centered scaled.

3. Results {#sec3}
==========

3.1. Baseline characteristics of the study participants {#sec3.1}
-------------------------------------------------------

A total of 72 participants were initially randomized in this study. Among these participants, nine participants dropped out. Among the nine dropouts, six participants withdrew consent because of adverse events or personal reasons, and three participants were excluded because of poor compliance. Thus, a total of 63 participants (29 in the ginseng berry group and 34 in the placebo group) who had completed the 12-wk treatment without major protocol violations and had a compliance rate of over 70% were analyzed for efficacy. All participants who entered the study and received at least one dose of the study medication were assessed for safety and demographics ([Fig. 2](#fig2){ref-type="fig"}). As shown in [Table 1](#tbl1){ref-type="table"}, there was no significant difference between the two groups in baseline demographic characteristics including sex, age, BMI, blood pressure, pulse rates, alcohol consumption, and smoking.Fig. 2Randomization scheme and participant disposition. AE, adverse event; SAE, serious adverse event.Table 1Baseline demographic characteristics of the study participantsGinseng berry group (*n* *=* 34)Placebo group (*n* *=* 38)Total\
(*n* *=* 72)*p*[1)](#tbl1fn1){ref-type="table-fn"}Sex (M/F)18 / 1624/ 1442 / 300.380[2)](#tbl1fn2){ref-type="table-fn"}Age (y)52.76 ± 10.2451.89 ± 9.4652.31 ± 9.780.709Height (cm)164.62 ± 9.23165.79 ± 8.63165.24 ± 8.880.580Weight (kg)69.57 ± 12.2270.89 ± 13.0470.27 ± 12.590.660BMI (kg/m^2^)25.52 ± 2.8725.61 ± 3.0525.57 ± 2.950.908SBP (mmHg)128.85 ± 13.75128.55 ± 14.56128.69 ± 14.080.929DBP (mmHg)82.38 ± 12.3281.16 ± 11.2781.74 ± 11.710.661Pulse (beats/min)73.91 ± 12.0873.76 ± 8.6473.83 ± 10.330.953AlcoholNo19 (55.88)13 (34.21)32 (44.44)0.065[2)](#tbl1fn2){ref-type="table-fn"}Yes15 (44.12)25 (65.79)40 (55.56)Amount of alcohol consumption (units[3)](#tbl1fn3){ref-type="table-fn"}/wk)14.55 ± 19.1312.46 ± 9.6413.26 ± 13.860.700SmokingNo27 (79.41)27 (71.05)54 (75.00)0.414[2)](#tbl1fn2){ref-type="table-fn"}Yes7 (20.59)11 (28.95)18 (25.00)Number of cigarettes/d19.29 ± 7.3215.90 ± 11.5517.29 ± 9.900.506[^1][^2][^3][^4][^5]

3.2. Efficacy {#sec3.2}
-------------

For both groups, within- and between-treatment differences in parameters of glucose or lipid metabolism were assessed ([Table 2](#tbl2){ref-type="table"}). There was no difference in serum concentration of glucose and insulin from the 75 g OGTT and HbA1c measures before and after the intervention. No difference for these parameters was found between the two groups. Also, there was no significant difference in the lipid profile for within- and between-treatment differences among participants in this study. In subgroup analyses in those with fasting glucose level of 110 mg/dL or higher ([Fig. 3](#fig3){ref-type="fig"}), however, serum concentration of fasting glucose significantly decreased by 3.7% (from a baseline of 120.25 ± 10.32 mg/dL to an endpoint value of 115.81 ± 9.30 mg/dL, *p* = 0.035) and that of postprandial glucose at 60 min during the 75 g OGTT also significantly decreased by 10.7% (from 231.75 ± 37.58 ng/dL to 206.94 ± 40.28 mg/dL, *p* = 0.006) in the ginseng berry group after intervention, while the placebo group did not exhibit such a statistically significant decrease. Total glucose area under the curve (AUC) of the ginseng berry group improved by 7.7% (23,090.63 ± 4,273.52 mg\*min/dL to 21,307.50 ± 4,298.89 mg\*min/dL, *p* = 0.024). There was a significant difference in between-treatment in 75 g OGTT indices of postprandial glucose level at 60 min (*p* = 0.017) and total glucose AUC (*p* = 0.040). However, there was no significant difference for within- and between-treatment in other parameters of glucose metabolism including HbA1c and insulin levels. When we conducted subgroup analyses by sex, we found that ginseng berry extract treatment in men induced a significant decrease of postprandial glucose level at 60 min (from a baseline of 213 ± 52.71 mg/dL to an end point value of 193 ± 44.89 mg/dL) during 75 g OGTT after intervention (*p* = 0.020), while placebo treatment in men did not show any effect on the same parameter. There was also a significant between-treatment difference in postprandial glucose level at 60 min (*p* = 0.046). However, there was no within- and between-treatment difference in women.Fig. 3Changes in serum glucose during 75 g oral glucose tolerance test before and after 12-wk intervention in subgroups with fasting glucose level of 110 mg/dL or higher. Values are presented as mean ± standard deviation. \**p* \< 0.05 serum concentration of fasting glucose after 12-wk intervention. \*\**p* \< 0.01 serum concentration of postprandial glucose at 60 min after 12-wk intervention. \*\*\**p* \< 0.05 serum concentration of postprandial glucose at 60 min in ginseng berry group compared with placebo group.Table 2Changes in serum glucose and insulin during 75 g OGTT, HbA1c, and lipid profile before and after interventionGinseng berry group (*n* *=* 29)Placebo group (*n* *=* 34)*p*[2)](#tbl2fn2){ref-type="table-fn"}Baseline12 wk*p*[1)](#tbl2fn1){ref-type="table-fn"}Baseline12 wk*p*[1)](#tbl2fn1){ref-type="table-fn"}Glu 0 min (mg/dL)112.31 ± 12.39112.03 ± 10.140.864112.88 ± 11.06112.79 ± 12.130.9570.935Glu 60 min (mg/dL)211.07 ± 45.46200.17 ± 44.110.085215.56 ± 45.91213.71 ± 45.460.7400.276Glu 120 min (mg/dL)174.03 ± 57.89173.48 ± 57.970.940171.44 ± 48.23170.76 ± 50.510.9200.990AUC-G (mg\*min/dL)21,254.48 ± 4,490.9820,575.86 ± 4,386.080.18821,463.24 ± 4,157.4021,329.12 ± 4,271.740.7830.439Ins 0 min (μU/mL)7.07 ± 4.017.10 ± 4.380.9627.06 ± 4.047.72 ± 5.370.4760.591Ins 60 min (μU/mL)46.28 ± 21.6847.09 ± 26.110.86448.66 ± 25.0852.86 ± 28.750.4170.630Ins 120 min (μU/mL)48.29 ± 23.2849.08 ± 27.440.87755.28 ± 27.5656.58 ± 30.050.7160.932AUC-I (μU\*min/mL)4,437.76 ± 1,864.944,510.68 ± 2,330.820.8544,789.61 ± 2,258.305,100.60 ± 2,502.900.4240.668HbA1c (%)5.85 ± 0.385.89 ± 0.410.5545.81 ± 0.375.81 ± 0.470.8970.675HOMA-IR2.01 ± 1.241.97 ± 1.240.8572.00 ± 1.242.16 ± 1.540.5420.559HOMA-β cell51.58 ± 27.2152.94 ± 31.570.77951.65 ± 29.3758.34 ± 40.100.3450.547Total cholesterol (mg/dL)190.07 ± 31.49191.62 ± 32.570.770197.88 ± 30.80203.59 ± 30.520.0600.476Triglyceride (mg/dL)^+^157.55 ± 115.56158.29 ± 148.050.833151.62 ± 76.33150.82 ± 83.460.9450.814LDL-cholesterol (mg/dL)122.07 ± 33.01117.48 ± 32.640.355131.15 ± 32.19133.94 ± 29.880.3150.176HDL-cholesterol (mg/dL)54.28 ± 14.3455.97 ± 18.140.31953.24 ± 13.6857.71 ± 18.310.002^∗∗^0.190[^6][^7][^8][^9]

3.3. Safety {#sec3.3}
-----------

There were no significant differences in number and type of reported adverse events for the two groups ([Table 3](#tbl3){ref-type="table"}). Only five adverse events were reported in the ginseng berry group, while 11 adverse events occurred in the placebo group. There was one serious adverse event reported in the placebo group and no cases in the ginseng berry group. In demographic profiles and vital signs, there were no differences in within- and between-treatment groups except for a significant decrease in diastolic blood pressure from a baseline of 79.93 ± 10.97 mmHg to an end point value of 73.93 ± 11.45 mmHg in the ginseng berry group (*p* = 0.010). When within- and between-treatment differences in safety laboratory parameters were assessed, there was a within-treatment difference in hematocrit (*p* = 0.047) and lymphocyte count (*p* = 0.034) in the ginseng berry group and a between-treatment difference in red blood cell count between the two groups (*p* = 0.042). However, these differences did not have clinical significance.Table 3Adverse eventsGinseng berry group (*n* *=* 34)Placebo group (*n* *=* 38)Overview of AEs ≥1 AEs5 (14.71)11 (28.95) ≥1 serious AEs01 (2.63) AE leading to discontinuation2 (5.88)2 (5.26)Common AEs[1)](#tbl3fn1){ref-type="table-fn"} (≥ 5%) Common cold1 (2.94)2 (5.26) Urticaria02 (5.26)Other AEs Gastric soreness1 (2.94)0 Epigastric pain1 (2.94)0 Cystitis1 (2.94)0 Periorbital edema01 (2.94) Herpes zoster01 (2.94) Rheumatoid knee pain01 (2.94) Rheumatoid trigger thumb01 (2.94) Sprain of lumbar spine01 (2.94) Severe cervical dysplasia01 (2.94) Urolithiasis1 (2.94%)0 Tinea pedis01 (2.94)Serious AEs Demyelinating disease01 (2.94)[^10][^11][^12]

3.4. Metabolomic profiling of serum of the study participants {#sec3.4}
-------------------------------------------------------------

For the metabolomic profiling of the participants (who were grouped into 2 as the ginseng berry group and the placebo group), blood samples were collected at the beginning (baseline) and 12 wk after the start of experiment, and the samples were subjected to UPLC/Q-TOF-MS. The metabolomics analysis identified 53 metabolites, listed in [Table S1](#appsec1){ref-type="sec"}. Also variable importance of projection (VIP) scores of the metabolites corresponding to ginseng berry consumption are presented. The intensity of the identified 53 metabolites in human blood samples is shown in [Table S2](#appsec1){ref-type="sec"}. There were no significant differences between the ginseng berry group and the placebo group during the 12 wk of treatment. No significant differences in intensity of metabolites were observed in the placebo group prior to the trial and after the 12-wk treatment (*p* \> 0.05). However, as the pre- and post-treatment blood samples in the ginseng berry group were compared, a significant decrease in the levels of the following metabolites was observed: valine (*p* = 0.027), leucine/isoleucine (*p* = 0.011), glutamine (*p* = 0.004), methionine (*p* = 0.017), xanthine (*p* = 0.005), and phenylpyruvic acid (*p* = 0.012). At the same time, there was a significant increase in levels of glycerophosphocholine (*p* = 0.012), linoleoyl carnitine (*p* = 0.015), lysophosphatidylethanolamine (18:2; *p* = 0.011), and lysophosphatidylcholine (20:2; *p* = 0.053). Pearson\'s correlation analysis was also conducted to assess the relationship between phenotypic and metabolomic changes. As shown in [Fig. S1 and S2](#appsec1){ref-type="sec"}, significant metabolomic changes in the ginseng berry group closely correlated with several phenotypic changes. Briefly, changes in fasting blood glucose level positively correlated with levels of xanthine (r = 0.531, *p* = 0.003), alanine (r = 0.430, *p* = 0.018), succinic acid (r = 0.668, *p* \< 0.001), phenylalanine (r = 0.450, *p* = 0.013), creatine (r = 0.385, *p* = 0.036), and leucine/isoleucine (r = 0.432, *p* = 0.017; [Fig. S1](#appsec1){ref-type="sec"}). The postprandial blood glucose at the 60-min level showed a significant positive correlation with levels of alanine (r = 0.559, *p* = 0.001), succinic acid (r = 0.458, *p* = 0.012), creatine (r = 0.427, *p* = 0.019), lysophosphatidylcholine (20:5; r = 0.535, *p* = 0.002), and lysophosphatidylcholine (22:6; r = 0.471, *p* = 0.009) and negatively correlated with level of corticosterone (r = 0.499, *p* = 0.005) ([Fig. S2](#appsec1){ref-type="sec"}). Based on these results, metabolomic changes for each participant in the ginseng berry group were clearly observed, although the overall changes in the ginseng berry group were not significantly different from those in the placebo group.

4. Discussion {#sec4}
=============

Ginseng consists of several parts including root, leaf, and berry. Generally, ginseng root has been widely used as traditional medicine for thousands of yr in Asia. Compared to the ginseng root, the berry portion of ginseng has not been commonly used for medical purposes. Meanwhile, the major active components of ginseng are reported to be ginsenosides, a class of natural product steroid glycosides and triterpene saponins [@bib26]. Although \> 30 ginsenosides have been isolated from various parts of ginseng including root and berry, the most common ginsenosides based on HPLC analysis include Rb1, Rb2, Rc, Rd, Re, Rf, and Rg1 [@bib27]. While the ginseng root has long been the favored source of these active ingredients, recent studies have shown that the ginseng berry contains higher levels of ginsenoside content and with a distinct ginsenoside profile compared with the ginseng root [@bib23], [@bib24]. The ginsenoside Re in particular was four- to six-times higher in the berry than in the root of ginseng [@bib24]. For this reason, each part of the plant may exhibit different pharmacological activities. Since the 1980s, the number of published studies exploring the effects of ginseng on glucose metabolism has remarkably increased. This includes reports demonstrating the therapeutic efficacy and mechanism of antihyperglycemic activity of ginseng root extracts in multiple *in vitro* [@bib8], [@bib9] and *in vivo* studies using various diabetic animal models [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19]. More recent studies have shown that not only root but also berry of ginseng has a potent antihyperglycemic activity [@bib14], [@bib15]. Furthermore, Dey et al [@bib23] compared the antihyperglycemic activity between ginseng root and berry in C57BL/6J *ob/ob* mice and concluded that ginseng berry is more potent than ginseng root in terms of glucose reduction when used at the same dosage. It was demonstrated that administration of ginsenoside Re, a major constituent of ginseng berry, significantly improved glucose tolerance without affecting body weight in C57BL/6J *ob/ob* mice [@bib14], [@bib28], which suggests that ginsenoside Re plays a crucial pharmacological role in glucose metabolism.

Several clinical trials investigating the effects of ginseng on diabetes-related parameters in human volunteers have been published, although the results from these studies have varied considerably [@bib20], [@bib21], [@bib22], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33]. Until recently, most clinical studies with ginseng have been conducted with its root. As far as we know, the present study is the first clinical trial to investigate the antihyperglycemic activity of ginseng berry in human volunteers. In this study, although we could not find significant differences within- and between-treatment for glucose and lipid metabolism in the total number of participants, we observed significant improvements in serum concentration of fasting and postprandial glucose at 60 min during 75 g OGTT in those with fasting glucose level of 110 mg/dL or higher, which implies that ginseng berry extract may be more beneficial to people with higher glucose levels.

At present, the mechanisms underlying ginseng\'s antidiabetic activity are not fully understood. A growing number of evidence from *in vitro* and *in vivo* studies suggest that the antihyperglycemic actions of ginseng are complex and attributable to various mechanisms including regulation of insulin secretion or sensitivity, modulation of gastrointestinal absorption, and regulation of inflammatory pathway [@bib34]. A recent animal study showed that treatment with ginseng berry extract significantly increased insulin secretion in β-cell-deficient diabetic mice induced by streptozotocin [@bib35]. In this study, the proliferation of β-cells by ginseng berry extract was also demonstrated *in vitro*. Another animal study using aged C57BL/6 mice showed that ginseng berry extract feeding significantly decreased HOMA-IR and fasting insulin levels, and ameliorated pancreatic islet hypertrophy, which suggests that the improvement of insulin sensitivity might contribute to a decrease in insulin demand [@bib36]. In the same study, it was also demonstrated that ginseng berry extract could activate insulin receptor substrate-1 and protein kinase B, the important molecules in the insulin signaling pathway. In our study, we showed that ginseng berry treatment induced metabolomic changes, some of which were associated with blood glucose level. This finding suggests that metabolomic changes by ginseng berry treatment might be involved in its antihyperglycemic activity, although we need further investigation to give a detailed account for it.

In the present study, there was no difference of HbA1c levels between control and ginseng berry group at the end of the study. We speculate that the lack of improvement in HbA1c levels by ginseng berry might be due to the participants\' well-controlled glucose status when they were enrolled in the study. The baseline mean value of HbA1c was 5.83% at the beginning of the study and most of our participants had a prediabetic condition rather than a diabetes mellitus one. Nevertheless, we found a significant improvement in postprandial glucose levels at 60 min during OGTT in those with fasting glucose levels of 110 mg/dL or higher. Recently, the importance of postprandial hyperglycemia has been highlighted [@bib37], as uncontrolled postprandial hyperglycemia can increase glucose variability. It was suggested that fluctuating glucose produces oxidative stress, thereby inducing endothelial dysfunction and inflammation, both well-known risk factors for cardiovascular disease [@bib38]. The relationship between postprandial hyperglycemia and the risk of cardiovascular event was identified in type 2 diabetes [@bib39]. Furthermore, it was shown that treating postprandial hyperglycemia by acarbose may reduce the incidence of cardiovascular disease in people with impaired glucose tolerance or type 2 diabetes [@bib40], [@bib41].

The limitations of the present study include the following. First, most participants enrolled in the present study were prediabetic. Only a small number of participants were diagnosed with type 2 diabetes. Therefore, caution should be used when we generalize these results to people with type 2 diabetes. In addition, with having only slightly higher than normal levels of fasting glucose in the total population of this study made it difficult to find a significant improvement in parameters related to glucose metabolism. Second, the lack of follow-up data in the dropouts precluded intention-to-treat analyses in order to strengthen the interpretation of the data.

In summary, the present study was the first randomized, double-blind, placebo-controlled clinical trial to examine the efficacy and safety of *P. ginseng* berry extract on glycemic control in human volunteers. Although the present study failed to show significant antihyperglycemic effects of ginseng berry extract on parameters related to glucose and lipid metabolism in the total study population, it demonstrated that compared with placebo, ginseng berry extract can significantly improve the fasting and postprandial glucose levels over 12 wk in those with fasting glucose levels of 110 mg/dL or higher. This study also showed that there was no safety concern with the long-term consumption of ginseng berry extract. In conclusion, the results of our study suggest that ginseng berry extract has the potential to improve glucose metabolism in humans, particularly those with fasting glucose levels of 110 mg/dL or higher, and without safety concerns. Further research in people with higher glucose levels is required.
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[^1]: Values are presented as mean ± standard deviation or *n* (%)

[^2]: BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure

[^3]: Analyzed by independent *t* test except sex (M/F), alcohol (No/Yes), and smoking (No/Yes)

[^4]: Analyzed by Chi-square test

[^5]: 1 unit = 10 g of pure alcohol

[^6]: Values are presented as mean ± standard deviation

[^7]: AUC-G, area under the curve for glucose; AUG-I, area under the curve for insulin; Glu, glucose; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment-insulin resistance; HOMA-β cell, homeostasis model assessment-β cell function; Ins, insulin; LDL, low-density lipoprotein; OGTT, oral glucose tolerance test

[^8]: For within-treatment differences analyzed by paired *t* test

[^9]: For between-treatment differences analyzed by linear mixed model for repeated measures data

[^10]: Values are presented as *n* (%)

[^11]: AEs, adverse events

[^12]: AEs with frequency ≥ 5% in any group
